Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: Selection of phase III trial dose

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 3, 2010, Pages 375-382

  Leil, T A ^a   Feng, Y ^a   Zhang, L ^a   Paccaly, A ^a   Mohan, P ^a   Pfister, M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; ENOXAPARIN; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VENOUS THROMBOEMBOLISM;

AGED; AREA UNDER CURVE; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; KIDNEY DISEASES; MALE; MODELS, BIOLOGICAL; PYRAZOLES; PYRIDONES; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 77955926663     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.106     Document Type: Article

References (33)

1. Geerts, W.H. et al. Prevention of venous thromboembolism: the seventh ACCp Conference on Antithrombotic and thrombolytic therapy. Chest 126, 338s-400s (2004).
2. Hirsh, J. & Raschke, R. Heparin and low-molecular-weight heparin: the seventh ACCp Conference on Antithrombotic and thrombolytic therapy. Chest 126, 188s-203s (2004). (Pubitemid 39297954)
3. Campbell, C.L. New treatment options for acute coronary syndromes. Am. J. Manag. Care 12, s435-s443 (2006).
4. O'Donnell, M. & Weitz, J.I. Novel antithrombotic therapies for the prevention of stroke in patients with atrial fbrillation. Am. J. Manag. Care 10, s72-s82 (2004).
5. Kubitza, D. & Haas, S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin. Investig. Drugs 15, 843-855 (2006).
6. Bauersachs, R.M. [New anticoagulants]. Hamostaseologie. 28, 21-26 (2008).
7. Jiang, X., Crain, E.J., Luettgen, J.M., Schumacher, W.A. & Wong, P.C. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb. Haemost. 101, 780-782 (2009).
8. Raghavan, N. et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab. Dispos. 37, 74-81 (2009).
9. Lassen, M.R., Davidson, B.L., Gallus, A., Pineo, G., Ansell, J. & Deitchman, D. The efcacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J. Thromb. Haemost. 5, 2368-2375 (2007).
10. Suryawanshi, S., Zhang, L., Pfster, M. & Meibohm, B. The current role of model-based drug development. Expert Opin. Investig. Drugs 5, 10 (2010).
11. Zhang, L., Pfster, M. & Meibohm, B. Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J. 10, 552-559 (2008).
12. Pfster, M., Martin, N.E., Haskell, L.P. & Barrett, J.S. Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240. J. Clin. Pharmacol. 44, 621-631 (2004).
13. Wang, Y. et al. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. J. Clin. Pharmacol. 48, 146-156 (2008).
14. Bhattaram, V.A. et al. Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006. Clin. Pharmacol. Ther. 81, 213-221 (2007).
15. Bhattaram, V.A. et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J. 7, E503-E512 (2005).
16. Holford, N.H. Concepts and usefulness of pharmacokinetic-pharmacodynamic modelling. Fundam. Clin. Pharmacol. 4 (suppl. 2), 93s-101s (1990).
17. Sheiner, L.B. & Steimer, J.L. pharmacokinetic/pharmacodynamic modeling in drug development. Annu. Rev. Pharmacol. Toxicol. 40, 67-95 (2000).
18. Lalonde, R.L. et al. Model-based drug development. Clin. Pharmacol. Ther. 82, 21-32 (2007).
19. Sheiner, L.B. Learning versus confrming in clinical drug development. Clin. Pharmacol. Ther. 61, 275-291 (1997).
20. Poland, B. et al. The clinical utility index as a practical multiattribute approach to drug development decisions. Clin. Pharmacol. Ther. 86, 105-108 (2009).
21. Smart, A. A multi-dimensional model of clinical utility. Int. J. Qual. Health Care 18, 377-382 (2006).
22. Frost, C., Yu, Z., Nepal, S., Mosqueda-Garcia, R & Shenker, A. Apixaban, an oral direct, factor Xa inhibitor: single-dose safety, pharmacokinetics and pharmacodynamics in healthy subjects. J. Thromb. Haemost. 5 (suppl. 2), p-M-665 (2007).
23. Gangireddy, C. et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J. Vasc. Surg. 45, 335-341; discussion 341 (2007).
24. Vera-Llonch, M., Hagiwara, M. & Oster, G. Clinical and economic consequences of bleeding following major orthopedic surgery. Thromb. Res. 117, 569-577 (2006).
25. Us Department of Health and Human services, Food and Drug Administration. Pharmacokinetics in Patients with Impaired Renal Function\Study Design, Data Analysis, and Impact on Dosing and Labeling. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), 1998.
26. Qadan, M., Tyson, M., McCaferty, M.H., Hohmann, S.F. & Polk, H.C. Jr. Venous thromboembolism in elective operations: balancing the choices. Surgery 144, 654-660, discussion 660 (2008).
27. Fuji, T., Ochi, T., Niwa, S. & Fujita, S. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. J. Orthop. Sci. 13, 442-451 (2008).
28. Spinler, S.A. et al.; For the sYNERGY trial Investigators. Relationship between renal function and outcomes in high-risk patients with non-st-segment elevation acute coronary syndromes: Results from sYNERGY. Int. J. Cardiol. (2009); e-pub ahead of print 28 April 2009.
29. Green, B. & Dufull, S.B. prospective evaluation of a D-optimal designed population pharmacokinetic study. J. Pharmacokinet. Pharmacodyn. 30, 145-161 (2003)
30. Bonate, P.L. Pharmacokinetic-Pharmacodynamic Modeling and Simulation. 387 (springer science + Business Media, New York, 2006).
31. Cockcroft, D.W. & Gault, M.H. prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41 (1976).
32. Agoram, B., Heatherington, A.C. & Gastonguay, M.R. Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. AAPS J. 8, E552-E563 (2006).
33. Beal, S. & Sheiner, L.B. NONMEM User's Guides. (University of California: san Francisco, 1998).